Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:DRUGNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriaCell Therapeutics$4.29-4.2%$3.99$3.00▼$36.60$15.91M1.34278,006 shs498,565 shsDRUGBright Minds Biosciences$33.11+3.4%$35.03$0.93▼$79.02$233.23M-5.5820,112 shs26,017 shsRXRXRecursion Pharmaceuticals$5.50+3.4%$6.66$3.79▼$12.36$2.21B112.00 million shs12.71 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriaCell Therapeutics-4.24%+6.98%+10.57%-24.34%-86.76%DRUGBright Minds Biosciences+3.44%+15.13%-7.18%-9.98%+2,804.39%RXRXRecursion Pharmaceuticals+3.38%+21.95%-13.93%-15.77%-26.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriaCell Therapeutics1.2097 of 5 stars3.52.00.00.00.00.00.6DRUGBright Minds Biosciences2.4889 of 5 stars3.65.00.00.00.62.50.0RXRXRecursion Pharmaceuticals2.1814 of 5 stars3.22.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriaCell Therapeutics 3.00Buy$32.00645.92% UpsideDRUGBright Minds Biosciences 3.20Buy$84.33154.71% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$8.2049.09% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, DRUG, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.004/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/28/2025RXRXRecursion PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/28/2025RXRXRecursion PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.002/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.002/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/3/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $32.001/23/2025DRUGBright Minds BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$93.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriaCell TherapeuticsN/AN/AN/AN/A($2.20) per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/ARXRXRecursion Pharmaceuticals$58.49M37.80N/AN/A$1.98 per share2.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriaCell Therapeutics-$4.79M-$5.03N/AN/AN/AN/AN/A-191.19%6/13/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.17N/AN/AN/AN/A-5.85%-5.68%5/21/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/8/2025 (Estimated)Latest BCTX, DRUG, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44N/AN/AN/A$18.12 millionN/A3/17/2025Q2 2025BCTXBriaCell Therapeutics-$1.94-$2.33-$0.39-$2.33N/AN/A2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million2/13/2025Q1 2025DRUGBright Minds Biosciences-$0.23$0.01+$0.24$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriaCell TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriaCell TherapeuticsN/A1.651.65DRUGBright Minds BiosciencesN/A126.0111.31RXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriaCell Therapeutics15.42%DRUGBright Minds Biosciences40.52%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipBCTXBriaCell Therapeutics5.73%DRUGBright Minds Biosciences42.66%RXRXRecursion Pharmaceuticals15.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriaCell Therapeutics83.71 million3.50 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableRXRXRecursion Pharmaceuticals400401.99 million329.18 millionOptionableBCTX, DRUG, and RXRX HeadlinesRecent News About These CompaniesFranklin Resources Inc. Increases Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 18 at 3:13 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.2% - Here's WhyApril 17 at 2:25 PM | marketbeat.comRecursion and HealthVerity announce agreementApril 17 at 4:10 AM | markets.businessinsider.comJPMorgan Chase & Co. Sells 119,024 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 17 at 3:14 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.4% - Time to Buy?April 16 at 1:46 PM | marketbeat.comHealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World DataApril 16 at 8:30 AM | prnewswire.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Carroll Investors IncApril 16 at 6:25 AM | marketbeat.comCapital Fund Management S.A. Purchases New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 16 at 4:24 AM | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Geode Capital Management LLCApril 16 at 3:23 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - Time to Buy?April 15 at 12:09 PM | marketbeat.comCathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals todayApril 15 at 3:40 AM | markets.businessinsider.comWhy Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?April 15 at 3:40 AM | msn.comWhy Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?April 15 at 2:14 AM | insidermonkey.comStrength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?April 14, 2025 | zacks.comAnalysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)April 14, 2025 | markets.businessinsider.comTop 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRXApril 14, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's What HappenedApril 13, 2025 | americanbankingnews.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.25 Consensus Price Target from BrokeragesApril 13, 2025 | americanbankingnews.comInvestors Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)April 13, 2025 | americanbankingnews.comWhy Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?April 13, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.6% Higher - Still a Buy?April 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsCan Solid Biosciences Challenge Sarepta in the DMD Market?By Leo Miller | April 8, 2025View Can Solid Biosciences Challenge Sarepta in the DMD Market?BCTX, DRUG, and RXRX Company DescriptionsBriaCell Therapeutics NASDAQ:BCTX$4.29 -0.19 (-4.24%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.22 -0.07 (-1.61%) As of 04/17/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Bright Minds Biosciences NASDAQ:DRUG$33.11 +1.10 (+3.44%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$33.06 -0.05 (-0.17%) As of 04/17/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Recursion Pharmaceuticals NASDAQ:RXRX$5.50 +0.18 (+3.38%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.52 +0.01 (+0.27%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Tariff-Resistant Abbott Laboratories on Track for New Highs Goldman Sachs Just Revealed What’s Next for Markets United Airlines Is in Reversal—If the Economy Doesn’t Stall Buy the Boeing Dip Even on Tariff and Bans? Spotify Stock Climbs as Its Growth Strategy Diversifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
